Tracked deals
4
4 tracked deals across 2019-2024.
Private Equity Firm
Healthcare
Bourne Partners Strategic Capital
Charlotte, North Carolina, United States
Healthcare investment affiliate of Bourne Partners that partners with and invests in pharmaceutical and pharmaceutical services companies and management teams, where it can add long-term strategic value.
- Focus Areas
- Pharmaceuticals, Pharmaceutical services, Pharmacy Benefit Management (PBM)
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Addon
1 addon · 1 buyout · 1 divestiture
Bourne Partners Strategic Capital Acquisition Volume by Year
Last 4 years
Supporting Data
Recent Transactions
-
- Buyer
- Ampersand Capital Partners, Bourne Partners Strategic Capital, Great Point Partners
- Target
- MedPharm, Tergus Pharma
- Industry
- Pharmaceuticals
- Location
- United Kingdom
- Type
- Addon
MedPharm and Tergus Pharma have merged and will operate under the MedPharm name to create an integrated, end-to-end topical and transdermal CDMO. Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership of the combined company while Great Point Partners retains a significant minority stake; Michael Kane is appointed CEO and Patrick Walsh remains Executive Chairman.
-
February 1, 2022
- Buyer
- Hildred Capital Management, LLC, Bourne Partners Strategic Capital, The Emerson Group
- Target
- Zegerid OTC
- Seller
- Bayer AG
- Industry
- Pharmaceuticals
- Location
- United States
- Type
- Divestiture
Hildred Capital, Bourne Partners Strategic Capital and The Emerson Group launched Carlin Consumer Health and acquired the Zegerid OTC brand from Bayer AG to establish a consumer health/OTC platform. The investors plan to invest in marketing, sales and product development to grow the Zegerid brand across U.S. retail channels; financial terms were not disclosed.
-
October 29, 2020
- Buyer
- Bourne Partners Strategic Capital, Meeting Street Capital
- Target
- Cadence Rx
- Industry
- Healthcare Services
- Location
- Florida, United States
- Type
- Growth capital
Bourne Partners Strategic Capital (BPSC) and Meeting Street Capital (MSC) jointly led a Series A growth equity investment in Cadence Rx, a workers' compensation-focused pharmacy benefit manager (PBM) founded by Artemis Emslie. The funding will support scaling Cadence Rx's tech-enabled PBM platform to reduce drug spend and expand program management for workers' compensation carriers, third-party administrators, self-insured employers and state-run enterprises.
-
November 6, 2019
- Buyer
- Enhanced Healthcare Partners, Bourne Partners Strategic Capital
- Target
- Pharmaceutical Associates, Inc.
- Industry
- Pharmaceuticals
- Location
- South Carolina, United States
- Type
- Buyout
Enhanced Healthcare Partners (EHP), together with Bourne Partners Strategic Capital (BPSC), announced the acquisition of Pharmaceutical Associates, Inc. (PAI), a U.S. manufacturer of generic liquid and unit-dose pharmaceuticals. The investment will provide growth capital to expand PAI's manufacturing capacity, product lines and market footprint while leveraging BPSC's pharmaceutical network and EHP's healthcare investment experience.
Related Acquisition Pages
Pharmaceuticals Buyers & Acquisitions
3 tracked deals by Bourne Partners Strategic Capital.
Healthcare Services Buyers & Acquisitions
1 tracked deal by Bourne Partners Strategic Capital.
Acquisitions in Florida
1 tracked deal by Bourne Partners Strategic Capital.
Acquisitions in South Carolina
1 tracked deal by Bourne Partners Strategic Capital.
Selling a company? Get in front of buyers like Bourne Partners Strategic Capital
Turn tracked acquisition activity into an outreach-ready buyer list.